InsiderSignal.AI

InsiderSignal.ai

IMVT - Immunovant, Inc.

Insider Sale by Venker Eric (CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Venker Eric, serving as CEO at Immunovant, Inc. (IMVT), sold 14,229 shares at $24.10 per share, for a total transaction value of $342,854.00. Following this transaction, Venker Eric now holds 19,561 shares of IMVT.

This sale represents a 42.00% decrease in Venker Eric's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, April 2, 2026 and publicly disclosed via SEC Form 4 filing on Friday, April 3, 2026, 1 day after the trade was made.

Immunovant, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Venker Eric

CEO

Eric Venker, M.D., Pharm.D., is the President of Roivant Sciences Ltd. (NASDAQ: ROIV) and Chief Executive Officer of its subsidiary Immunovant.[[1]](https://www.investing.com/news/insider-trading-news/roivant-sciences-president-venker-sells-404-million-in-shares-93CH-4344271)[[2]](https://fintool.com/app/research/companies/ROIV/people/eric-venker)[[5]](https://www.roivant.com/about/leadership) He joined Roivant in 2014, previously serving as President and COO before his current roles.[[2]](https://fintool.com/app/research/companies/ROIV/people/eric-venker)[[4]](https://www.nasdaq.com/articles/immunovant-announces-leadership-changes-eric-venker-appointed-ceo-and-tiago-girao-cfo)[[5]](https://www.roivant.com/about/leadership) Dr. Venker has been actively involved in recent insider trading activities, including selling 200,000 shares on November 7, 2025, for $4.04 million after exercising options, and another 200,000 shares on January 12, 2026.[[1]](https://www.investing.com/news/insider-trading-news/roivant-sciences-president-venker-sells-404-million-in-shares-93CH-4344271)[[3]](https://www.tradingview.com/news/tradingview:6d066f8976c8c:0-roivant-sciences-executive-sells-200-000-shares/) His leadership aligns with Roivant's advancements, such as positive Phase 3 trial results for brepocitinib in dermatomyositis.[[1]](https://www.investing.com/news/insider-trading-news/roivant-sciences-president-venker-sells-404-million-in-shares-93CH-4344271)

View full insider profile →

Trade Price

$24.10

Quantity

14,229

Total Value

$342,854.00

Shares Owned

19,561

Trade Date

Thursday, April 2, 2026

3 days ago

SEC Filing Date

Friday, April 3, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Immunovant, Inc.

Company Overview

No company information available
View news mentioning IMVT

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5334158

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime